Graft-versus-host disease | PressReleasePoint

Status message

SESSION['ACCESSGRANTED'] value is

Post date	Title	Picture
Fri, 08/22/2025 - 01:40	ReAlta Life Sciences Receives EMA Orphan Drug Designation for RLS-0071 (pegtarazimod) for the Treatment of Graft-Versus-Host Disease	VABIO
Thu, 03/27/2025 - 18:06	Machine Learning Program Enhances Transplant Risk Assessment in Myelofibrosis Patients	American Societ...
Wed, 02/12/2025 - 22:51	Dana-Farber Researchers to Present Key Transplant and Cellular Therapy Studies at 2025 Tandem Meetings	Dana Farber
Thu, 12/19/2024 - 00:39	FDA Approves First Mesenchymal Stromal Cell Therapy to Treat Steroid-refractory Acute Graft-versus-host Disease	FDA
Tue, 08/27/2024 - 21:05	Low-intensity blood stem cell transplants for sickle cell appear safe for lung health	NIH
Tue, 08/06/2024 - 08:00	Final Results of Phase 2 Clinical Trial Clarify Role of JAK2 Inhibitor in Combating Acute Graft-Versus-Host Disease	Roswell Park Ca...
Tue, 10/11/2022 - 12:16	Expert alert: Five key medical advances related to bone marrow transplantation	Mayo Clinic
Tue, 09/06/2022 - 11:49	Cell therapy could improve bone marrow transplant safety	UCLA
Sat, 04/23/2022 - 16:52	Roswell Park Specialists to Highlight Latest Advances in Blood Cancer Treatment and Cellular Therapy	Roswell Park Ca...
Wed, 12/15/2021 - 16:15	FDA approval offers hope for prevention of acute graft-versus-host disease	Dana Farber
Fri, 10/08/2021 - 19:52	FDA Approves Innovative Treatment for Pediatric Patients with Congenital Athymia	FDA
Thu, 09/30/2021 - 18:53	Fujifilm agrees on core terms with Australian regenerative medicine venture Cynata to manufacture Cynatas iPS cell-derived regenerative medicine products	Fujifilm
Fri, 06/25/2021 - 12:33	Immunosuppressant CellCept, Approved for Additional Indication of Prevention of Graft-Versus-Host Disease in Hematopoietic Stem-Cell Transplantation	Chugai
Tue, 06/08/2021 - 18:17	Incyte Announces U.S. FDA Has Extended the sNDA Review Period for Ruxolitinib (Jakafi) in Chronic Graft-Versus-Host Disease (GVHD)	Incyte
Mon, 03/22/2021 - 09:14	Phase 1 Trial Demonstrates Encouraging Clinical Benefit and Promising Safety Profile of Pacritinib for the Prevention of Graft-Versus-Host Disease Published in Clinical Cancer Research	CTI BioPharma
Sun, 12/06/2020 - 05:37	CTI BioPharma Announces Presentation of Data Supporting Pacritinib's Potential Benefit in Preventing Acute GVHD at the 62nd American Society of Hematology Meeting	CTI BioPharma
Tue, 07/28/2020 - 10:25	Stemedica in the News! ProMedica Researchers Observe Encouraging Outcomes with Use of Allogeneic Stem Cells in COVID-19 Patients	Stemedica
Tue, 07/14/2020 - 15:50	Umbilical Cord Blood Treats Rare Genetic Diseases	Children's Hosp...
Wed, 05/20/2020 - 00:56	Cidara Therapeutics Doses First Patient in Pivotal Phase 3 ReSPECT Trial of Rezafungin for Prevention of Invasive Fungal Disease in Patients Undergoing Allogeneic Blood and Marrow Transplantation	Cidara Therapeutics
Thu, 05/07/2020 - 04:09	Researchers have found accumulation of gene mutations in chronic Graft-versus-host disease	HelsinkiUniv
Wed, 04/29/2020 - 08:33	Jazz Pharmaceuticals Stops Enrollment in Phase 3 Study Evaluating Defibrotide for the Prevention of Veno-Occlusive Disease	Jazz Pharmaceuticals
Wed, 04/22/2020 - 02:37	Novartis announces data showing Jakavi (ruxolitinib) more effective than best available therapy in acute graft-versus-host disease	Novartis
Mon, 02/10/2020 - 00:29	City of Hopes Triplex vaccine reduces rate of CMV complications in transplant recipients by 50 percent and spurs immunity against the virus	City of Hope Na...
Wed, 01/15/2020 - 17:56	Mutations in donors stem cells may cause problems for cancer patients	Washington Univ...
Tue, 01/07/2020 - 08:40	Synthetic Biologics Receives FDA Guidance at Type C Meeting for SYN-004 (ribaxamase) Phase 1b/2a Clinical Trial in Allogeneic HCT Recipients	Synthetic Biologics

1
2
3
4
5
next ›
last »

Graft-versus-host disease Press Release

Status message